These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 26085906)

  • 1. Non-alcoholic fatty liver disease in 2015.
    Ahmed M
    World J Hepatol; 2015 Jun; 7(11):1450-9. PubMed ID: 26085906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Buffet C
    Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease: a diabetologist's perspective.
    Pappachan JM; Antonio FA; Edavalath M; Mukherjee A
    Endocrine; 2014 Apr; 45(3):344-53. PubMed ID: 24287794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Alcoholic Fatty Liver Disease.
    Brůha R
    Vnitr Lek; 2019; 65(9):571-575. PubMed ID: 31635468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.
    Hashimoto E; Tokushige K; Ludwig J
    Hepatol Res; 2015 Jan; 45(1):20-8. PubMed ID: 24661406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S; Duseja A
    Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of incretin hormones and glucagon in patients with liver disease.
    Junker AE
    Dan Med J; 2017 May; 64(5):. PubMed ID: 28552096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
    Moore JB
    Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-alcoholic steatohepatitis - from NAFLD to MAFLD].
    Balmer ML; Dufour JF
    Ther Umsch; 2011 Apr; 68(4):183-8. PubMed ID: 21452138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges.
    Dooghaie Moghadam A; Eslami P; Razavi-Khorasani N; Moazzami B; Zahedi-Tajrishi F; Farokhi E; Makhdoomi Sharabiani K; Mansour-Ghanaei A; Mehrvar A; Aghajanpoor Pasha M; Saeedi S; Iravani S
    Caspian J Intern Med; 2020; 11(4):346-354. PubMed ID: 33680375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
    Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
    Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growing challenge of post-liver transplantation non-alcoholic fatty liver disease.
    Kalogirou MS; Giouleme O
    World J Transplant; 2022 Sep; 12(9):281-287. PubMed ID: 36187880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.
    Milić S; Stimac D
    Dig Dis; 2012; 30(2):158-62. PubMed ID: 22722431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.